Log in to save to my catalogue

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizum...

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizum...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cfa232992c194eb9b490f0ff34e0deec

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

About this item

Full title

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Publisher

London: BMJ Publishing Group Ltd

Journal title

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A1011-A1012

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundIntratumoral immunotherapies are being tested in different solid tumors. They trigger local and systemic responses.1 2 BO-112 is a double stranded RNA nanoplexed with polyethyleneimine (PEI), which mimics a viral infection and mobilizes the immune system.In preclinical models and in a first in human clinical trial BO-112 activated dendrit...

Alternative Titles

Full title

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_cfa232992c194eb9b490f0ff34e0deec

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cfa232992c194eb9b490f0ff34e0deec

Other Identifiers

E-ISSN

2051-1426

DOI

10.1136/jitc-2021-SITC2021.961

How to access this item